Wintech Nano
688757
CHANGFU CO.,LTD
871396
DIER CHEMICAL
831304
4
CHENGUANG MEDICAL
430300
5
TLC
873576
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 28, 2024 | (Q2)Jun 29, 2024 | (Q1)Mar 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jul 1, 2023 | (Q1)Apr 1, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.41%10.82B | 5.69%3.01B | 9.15%2.79B | 9.36%2.63B | 10.04%2.39B | 9.50%9.98B | 5.25%2.85B | 7.71%2.56B | 12.29%2.4B | 2.17B |
Operating revenue | 8.41%10.82B | 5.69%3.01B | 9.15%2.79B | 9.36%2.63B | 10.04%2.39B | 9.50%9.98B | 5.25%2.85B | 7.71%2.56B | 12.29%2.4B | --2.17B |
Cost of revenue | 5.93%5.31B | 4.88%1.46B | 6.35%1.36B | 6.18%1.29B | 6.40%1.2B | 2.56%5.01B | 2.80%1.39B | -4.92%1.28B | 5.57%1.21B | 1.13B |
Gross profit | 10.91%5.51B | 6.46%1.55B | 11.95%1.43B | 12.62%1.34B | 13.96%1.19B | 17.52%4.97B | 7.70%1.46B | 24.15%1.28B | 20.10%1.19B | 1.05B |
Operating expense | 8.12%2.82B | 13.51%773M | 12.15%711M | 3.47%686M | 3.32%654M | 5.03%2.61B | 5.42%681M | -0.63%634M | 8.33%663M | 633M |
Selling and administrative expenses | 12.24%1.75B | 15.13%487M | 15.53%439M | 10.26%430M | 7.88%397M | 7.66%1.56B | 11.02%423M | 0.53%380M | 9.55%390M | --368M |
-General and administrative expense | ---- | ---- | 15.53%439M | ---- | ---- | ---- | ---- | 0.53%380M | ---- | ---- |
Research and development costs | 6.88%917M | 12.84%246M | 8.84%234M | 2.33%220M | 3.81%218M | 10.14%858M | 7.92%218M | 9.14%215M | 12.57%215M | --210M |
Depreciation amortization depletion | -14.12%152M | -5.00%38M | -2.56%38M | -16.28%36M | -29.09%39M | -31.13%177M | -36.51%40M | -38.10%39M | -33.85%43M | --55M |
-Depreciation and amortization | -14.12%152M | -5.00%38M | -2.56%38M | -16.28%36M | -29.09%39M | -31.13%177M | -36.51%40M | -38.10%39M | -33.85%43M | --55M |
Other operating expenses | -86.67%2M | ---- | ---- | ---- | ---- | --15M | --0 | ---- | --15M | ---- |
Operating profit | 13.99%2.69B | 0.26%776M | 11.76%722M | 24.14%653M | 30.27%538M | 35.34%2.36B | 9.79%774M | 64.38%646M | 39.15%526M | 413M |
Net non-operating interest income expense | -5.09%-227M | -7.69%-56M | -9.43%-58M | -21.05%-69M | 18.52%-44M | 4.42%-216M | 5.45%-52M | 11.67%-53M | -1.79%-57M | -54M |
Non-operating interest income | 106.06%68M | 63.64%18M | 114.29%15M | 200.00%18M | 88.89%17M | 135.71%33M | --11M | --7M | 100.00%6M | --9M |
Non-operating interest expense | 18.47%295M | 17.46%74M | 21.67%73M | 38.10%87M | -3.17%61M | 3.75%249M | -8.70%63M | 0.00%60M | 6.78%63M | --63M |
Other net income (expense) | -16,433.33%-490M | 585.71%68M | 3,200.00%31M | -122.22%-4M | -58,300.00%-584M | 250.00%3M | -207.69%-14M | -1M | 181.82%18M | -1M |
Gain on sale of security | -10.00%-22M | 57.14%-3M | 145.45%5M | 83.33%-2M | 18.18%-9M | 60.78%-20M | -133.33%-7M | 15.38%-11M | -71.43%-12M | ---11M |
Earnings from equity interest | --0 | ---- | ---- | -164.71%-11M | -166.67%-2M | --0 | ---- | ---- | 221.43%17M | --3M |
Special income (charges) | -617.07%-588M | 200.00%39M | 15.38%-11M | 10.00%-9M | -2,940.00%-608M | 10.87%-82M | -129.41%-39M | 38.10%-13M | 61.54%-10M | ---20M |
-Less:Restructuring and merger&acquisition | 58.62%46M | 90.00%19M | 80.00%9M | 60.00%8M | 22.22%11M | -29.27%29M | -9.09%10M | 25.00%5M | -44.44%5M | --9M |
-Less:Impairment of capital assets | -11.11%8M | 50.00%3M | --1M | -50.00%1M | -40.00%3M | -75.00%9M | -75.00%2M | --0 | -81.82%2M | --5M |
-Less:Other special charges | 13,175.00%531M | -2,133.33%-61M | 0.00%1M | ---- | --591M | -71.43%4M | 250.00%3M | -91.67%1M | ---- | ---- |
-Write off | -81.25%3M | --0 | --0 | --0 | -50.00%3M | 1,500.00%16M | --0 | --7M | --3M | --6M |
-Gain on sale of business | --0 | ---- | ---- | ---- | ---- | ---24M | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 14.29%120M | 0.00%32M | 60.87%37M | -21.74%18M | 29.63%35M | -14.63%105M | -5.88%32M | -32.35%23M | -8.00%23M | --27M |
Income before tax | -8.11%1.97B | 11.30%788M | 17.40%695M | 19.10%580M | -125.14%-90M | 41.65%2.15B | 6.79%708M | 77.78%592M | 62.33%487M | 358M |
Income tax | -9.72%390M | 58.56%176M | 3.94%132M | 18.42%135M | -165.82%-52M | 191.89%432M | 52.05%111M | 139.62%127M | 60.56%114M | 79M |
Net income | -7.70%1.58B | 2.51%612M | 21.08%563M | 19.30%445M | -113.62%-38M | 25.38%1.71B | 1.19%597M | 66.07%465M | 62.88%373M | 279M |
Net income continuous Operations | -7.70%1.58B | 2.51%612M | 21.08%563M | 19.30%445M | -113.62%-38M | 25.38%1.71B | 1.19%597M | 66.07%465M | 62.88%373M | --279M |
Minority interest income | 0.00%5M | 0.00%1M | 0.00%1M | 0.00%2M | 0.00%1M | 25.00%5M | 0.00%1M | 0.00%1M | 100.00%2M | 1M |
Net income attributable to the parent company | -7.72%1.58B | 2.52%611M | 21.12%562M | 19.41%443M | -114.03%-39M | 25.39%1.71B | 1.19%596M | 66.31%464M | 62.72%371M | 278M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -7.72%1.58B | 2.52%611M | 21.12%562M | 19.41%443M | -114.03%-39M | 25.39%1.71B | 1.19%596M | 66.31%464M | 62.72%371M | 278M |
Basic earnings per share | -7.62%9.45 | 2.23%3.66 | 20.86%3.36 | 19.91%2.65 | -113.86%-0.23 | 25.68%10.23 | 1.70%3.58 | 66.47%2.78 | 62.50%2.21 | 1.66 |
Diluted earnings per share | -7.05%9.23 | 2.59%3.56 | 21.85%3.29 | 20.93%2.6 | -114.29%-0.23 | 25.22%9.93 | 1.17%3.47 | 65.64%2.7 | 61.65%2.15 | 1.61 |
Dividend per share | 11.33%4.03 | 11.22%1.09 | 11.36%0.98 | 11.36%0.98 | 11.36%0.98 | 11.38%3.62 | 11.36%0.98 | 11.39%0.88 | 11.39%0.88 | 0.88 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |